Trial Profile
Use of doxorubicin liposomal not pegylated (MYOCET) as second-line chemotherapy in epithelial ovarian carcinoma: Carboplatin + Myocet in patients Platinum sensitive or Myocet as single agent in patients Platinum resistant.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2012
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jul 2011 New trial record